Programmed Death Receptor-1 Blocking Antibody [EPC] class drugs

11 results

  • jemperli - dostarlimab injection

    (Dostarlimab)
    Glaxosmithkline Llc
    Jemperli treats adults with primary advanced or recurrent endometrial cancer (combined with carboplatin/paclitaxel or as monotherapy for dMMR tumors), and dMMR recurrent or advanced solid tumors that progressed on prior treatment with no satisfactory alternative options.
    Medication Details
    Drug Interactions

  • keytruda - pembrolizumab injection, powder, lyophilized, for solution

    (Pembrolizumab)
    Merck Sharp & Dohme Llc
    KEYTRUDA is a PD-1 blocking antibody that treats multiple cancers—including melanoma, lung, head and neck, bladder, colorectal, gastric, cervical, breast, and renal cancers—as well as MSI-H/dMMR and TMB-H solid tumors, used across neoadjuvant, adjuvant, and metastatic settings.
    Medication Details
    Drug Interactions

  • loqtorzi - toripalimab - tpzi injection

    (Toripalimab-Tpzi)
    Coherus Biosciences, Inc.
    Loqtorzi is a PD-1 blocking antibody for adults with nasopharyngeal carcinoma (NPC): first-line with cisplatin and gemcitabine for metastatic or recurrent locally advanced NPC, or as monotherapy for recurrent unresectable or metastatic NPC after platinum-containing chemotherapy.
    Medication Details
    Drug Interactions

  • opdivo - nivolumab injection

    (Nivolumab)
    E.R. Squibb & Sons, L.L.C.
    Opdivo is a PD-1 blocking antibody indicated for multiple cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, and gastric cancers in adults and select pediatric patients.
    Medication Details
    Drug Interactions

  • opdualag - nivolumab and relatlimab - rmbw injection

    (Nivolumab And Relatlimab-Rmbw)
    E.R. Squibb & Sons, L.L.C.
    Opdualag treats unresectable or metastatic melanoma in adults and pediatric patients 12 years and older.
    Medication Details
    Drug Interactions

  • tecentriq - atezolizumab injection, solution

    (Atezolizumab)
    Genentech, Inc.
    Tecentriq is a PD-L1 blocking antibody indicated for non-small cell lung cancer (adjuvant and metastatic), extensive-stage small cell lung cancer, unresectable or metastatic hepatocellular carcinoma, BRAF V600 mutation-positive melanoma, and alveolar soft part sarcoma in adults and pediatric patients 2 years and older.
    Medication Details
    Drug Interactions